Team:UT Dallas/Safety
From 2011.igem.org
(Difference between revisions)
(3 intermediate revisions not shown) | |||
Line 3: | Line 3: | ||
<head> | <head> | ||
<title>biz solution</title> | <title>biz solution</title> | ||
- | <meta http-equiv="Content-Type" content=" | + | <meta http-equiv="Content-Type" content="texxt/html; charset=utf-8" /> |
<link href="style.css" rel="stylesheet" type="text/css" /> | <link href="style.css" rel="stylesheet" type="text/css" /> | ||
<script type="text/javascript" src="js/jquery-1.3.2.min.js"></script> | <script type="text/javascript" src="js/jquery-1.3.2.min.js"></script> | ||
Line 456: | Line 456: | ||
d. Risks to security through malicious misuse by individuals, groups or states? | d. Risks to security through malicious misuse by individuals, groups or states? | ||
- | Access to our building and laboratory is strictly limited by cardkey and is further | + | <p>Access to our building and laboratory is strictly limited by cardkey and is further. </p> |
overseen by security personnel at the building entrance.</p></blockquote> | overseen by security personnel at the building entrance.</p></blockquote> | ||
Line 473: | Line 473: | ||
planned parts raise safety issues and all other documentation will be available on our | planned parts raise safety issues and all other documentation will be available on our | ||
parts page.</p></blockquote> | parts page.</p></blockquote> | ||
- | <p><b>3. | + | <p><b>3. Under what biosafety provisions will / do you operate?</b></p> |
- | <blockquote>UT Dallas has an Institutional Biosafety Committee that manages all safety responsibilities under NIH “Guidelines for Research Involving Recombinant DNA Molecules”. Throughout the course of this work, we ensured that all lab activity respected safety measures.</blockquote> | + | <blockquote><p>a. Does your institution have its own biosafety rules and if so what are they? Provide a |
- | <p><b>4. Do you have | + | link to them online if possible.</p> |
- | <blockquote> | + | |
+ | <p>b. Does your institution have an Institutional Biosafety Committee or equivalent group? | ||
+ | If yes, have you discussed your project with them?</p> | ||
+ | |||
+ | <p>UT Dallas has an Institutional Biosafety Committee (http://provost.utdallas.edu/policy/ | ||
+ | utdpp1016) that manages all safety responsibilities under NIH “Guidelines for Research | ||
+ | Involving Recombinant DNA Molecules”. Throughout the course of this work, we | ||
+ | ensured that all lab activity respected safety measures.</p><p>Describe any concerns or changes that were made based on this review.</p> | ||
+ | |||
+ | <p>c. Will / did you receive any biosafety and/or lab training before beginning your project? | ||
+ | If so, describe this training.</p> | ||
+ | |||
+ | <p>Our instructors demonstrated use of all equipment and materials in accordance with | ||
+ | safety guidelines. This training included an emphasis on wearing protective gear at all | ||
+ | times, proper use of large machines such as the autoclave, waste disposal, and specific | ||
+ | comments on the use of EtBr-exposed materials.</p> | ||
+ | |||
+ | <p>d. Does your country have national biosafety regulations or guidelines? If so, provide a | ||
+ | link to them online if possible.</p> | ||
+ | |||
+ | <p>The NIH outlines specific “Guildlines for Research Involving Recombinant DNA | ||
+ | Molecules” (http://oba.od.nih.gov/rdna/nih_guidelines_oba.html), which were strictly | ||
+ | observed throughout the course of our project.</p></blockquote> | ||
+ | <p><b>4. OPTIONAL QUESTION: Do you have other ideas on how to deal with safety or | ||
+ | security issues that could be useful for future iGEM competitions? How could | ||
+ | parts, devices and systems be made even safer through biosafety engineering?</b></p> | ||
+ | <blockquote><font size = "3" face = "arial">As part of our project, we are engineering a systemic kill-switch whose induction can | ||
+ | be used to regulate the activity of cells harboring our BioBricks. This device will exist in | ||
+ | a secondary bacterial population that will confer an additional level of user control. We | ||
+ | would encourage fast-acting kill-switches as standard practice in synthetic biology to | ||
+ | enable immediate inactivation should significant risks to safety become evident.</font></blockquote> | ||
<br></br><br></br> | <br></br><br></br> |
Latest revision as of 04:56, 3 September 2011